Rationale, design, and baseline characteristics of ARTS-DN: A randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy

American Journal of Nephrology

Volumn 40, Issue 6, 2014, Pages 572-581

  Ruilope, Luis M ^a   Agarwal, Rajiv ^b   Chan, Juliana C ^c   Cooper, Mark E ^d   Gansevoort, Ron T ^e   Haller, Hermann ^f   Remuzzi, Giuseppe ^j,k   Rossing, Peter ^l   Schmieder, Roland E ^g   Nowack, Christina ^h   Ferreira, Anna C ^m   Pieper, Alexander ⁱ   Kimmeskamp Kirschbaum, Nina ^h   Bakris, George L ⁿ  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h BAYER PHARMA AG   (Germany)

ⁱ MARCO GmbH and Co KG   (Germany)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^k Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^l STENO DIABETES CENTER   (Denmark)

^m Global Development   (Brazil)

ⁿ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

more..

Author keywords

Antagonist; Diabetic nephropathy; Heart failure; Mineralocorticoid receptor; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FINERENONE; PLACEBO; POTASSIUM; ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE;

ADULT; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; DIABETIC NEPHROPATHIES; FAMILIAL PRIMARY PULMONARY HYPERTENSION; URINE;

AGED; ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; POTASSIUM;

EID: 84923587123     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000371497     Document Type: Article

References (39)

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, et al: US Renal Data System 2013 Annual Data Report. Am J Kidney Dis 2014; 63:A7.
2. Bakris GL, Molitch M: Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 2014; 37: 867-875.
3. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063.
4. de Jong PE, Gansevoort RT: Albuminuria in non-primary renal disease: risk marker rather than risk factor. Nephrol Dial Transplant 2010; 25: 656-658.
5. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, et al: Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-1364.
6. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
7. Schmieder RE, Schutte R, Schumacher H, Bohm M, Mancia G, et al: Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia 2014; 57: 2019-2029.
8. American Diabetes Association: Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(suppl 1):S14-S80.
9. Schmieder RE, Ruilope LM, Barnett AH: Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol 2011; 24: 569-580.
10. Kalaitzidis R, Bakris GL: Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl 2009; 27:S15-S21.
11. American Diabetes Association: Executive summary: standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (suppl 1):S5-S13.
12. Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, et al: Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 70-78.
13. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457-465.
14. Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492.
15. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH: Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939.
16. Horita Y, Taura K, Taguchi T, Furusu A, Kohno S: Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 2006; 11: 462-466.
17. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2009; 3:CD007004.
18. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
19. Chrysostomou A, Becker G: Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926.
20. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112.
21. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
22. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, et al: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
23. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
24. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
25. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, et al: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
26. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, et al: Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012; 7: 1385-1403.
27. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, et al: Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014; 64: 69-78.
28. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, et al: Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013; 34: 2453-2463.
29. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, et al: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213.
30. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
31. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, et al: Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369: 2492-2503.
32. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
33. Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, et al: Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail 2012; 18: 265-281.
34. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, et al: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147-e239.
35. Toto RD: Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol Hypertens 2010; 19: 444-449.
36. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, et al: Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012; 14: 668-675.
37. Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, et al: Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant 2013; 28: 2841-2850.
38. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, et al: Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13: 387-393.
39. Ruggenenti P, Cravedi P, Remuzzi G: The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319-330.